Late-Breaking Abstract on LB-100, Lixte Biotechnology–s Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
Picture Gallery, Venture Capital Thursday, March 9th, 2017
EAST SETAUKET, NY — (Marketwired) — 03/09/17 — Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade in a preclinical model" has been accepted for presentation as a poster (abstract number LB-193) at the American Association for Cancer Research Annual Meeting 2017 in Washing
